Further analysis reinforces survival benefit for KRAS inhibitor daraxonrasib in advanced pancreatic cancer
Additional reporting and commentary from ASCO 2026 consolidates the picture around Revolution Medicines' daraxonrasib, with coverage noting that demand from patients is already outpacing access to the investigational drug.
Several items in this feed cycle relate to Revolution Medicines' KRAS inhibitor daraxonrasib and its ASCO 2026 trial data in advanced pancreatic cancer. These items — covering patient access difficulties and further biotech commentary — follow substantial coverage already published by Genetic Current on 1 June 2026 (Revolution Medicines reports practice-changing trial results) and 4 June 2026 (daraxonrasib draws attention beyond pancreatic cancer).
The new reporting, from STAT News on 4–5 June 2026, adds the perspectives of patients and advocates who note that excitement around the drug is creating demand that current supply and compassionate access routes cannot meet, and that the drug's cost may place it out of reach for some. A podcast episode and separate biotech commentary piece cover similar ground.
These items do not present new primary data. They extend and contextualise findings already summarised. Readers seeking the primary trial analysis should refer to earlier Genetic Current coverage. The drug remains investigational and has not received regulatory approval.
Plain-language version
For patients, families, and general readers. Educational only — not medical advice.
Revolution Medicines has reported that its experimental drug daraxonrasib, which targets a specific molecular change called a KRAS mutation that drives many pancreatic cancers, showed a meaningful improvement in survival in a clinical trial presented at the American Society of Clinical Oncology meeting in June 2026. New reporting this week describes the situation facing patients who want access to the drug now, before it has been approved by regulators: supply is limited and costs are high, meaning many patients face uncertainty about whether and when they might be able to receive it.
The drug is still being studied and has not yet been approved for routine use. Researchers and patient advocates are calling attention to the access challenge as the scientific results attract wide interest.
This is an educational summary, not medical advice. If anything here raises questions for you, please speak with your GP or a clinical professional.
Sources
Read the original reporting — these are the public sources this summary draws from.
-
Primary source Stat News · 2026-06-04STAT+: For pancreatic cancer patients, an exciting drug can feel out of reach
-
Stat News · 2026-06-04What RevMed's pancreatic cancer drug meant for one patient
-
Stat News · 2026-06-05STAT+: Will Makary's FDA voucher program survive?